(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.02%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.54%.
Lb Pharmaceuticals's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast LBRX's earnings for 2026 to be -$103,740,656, with the lowest LBRX earnings forecast at -$104,543,603, and the highest LBRX earnings forecast at -$97,859,075. On average, 8 Wall Street analysts forecast LBRX's earnings for 2027 to be -$128,018,310, with the lowest LBRX earnings forecast at -$148,946,530, and the highest LBRX earnings forecast at -$112,914,317.
In 2028, LBRX is forecast to generate -$123,045,778 in earnings, with the lowest earnings forecast at -$146,417,250 and the highest earnings forecast at -$93,342,502.